97 related articles for article (PubMed ID: 11257710)
1. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.
Naughton M; Picus J; Zhu X; Catalona WJ; Vollmer RT; Humphrey PA
J Urol; 2001 Apr; 165(4):1325-8. PubMed ID: 11257710
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
Humphrey PA; Halabi S; Picus J; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
Clin Genitourin Cancer; 2006 Mar; 4(4):269-74. PubMed ID: 16729910
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer.
Hashem M; Essam T
J Egypt Natl Canc Inst; 2005 Jun; 17(2):114-20. PubMed ID: 16508682
[TBL] [Abstract][Full Text] [Related]
5. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
6. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer.
Eichbaum MH; de Rossi TM; Kaul S; Bruckner T; Schneeweiss A; Sohn C
Tumour Biol; 2007; 28(1):36-44. PubMed ID: 17143015
[TBL] [Abstract][Full Text] [Related]
8. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.
Gmyrek GA; Walburg M; Webb CP; Yu HM; You X; Vaughan ED; Vande Woude GF; Knudsen BS
Am J Pathol; 2001 Aug; 159(2):579-90. PubMed ID: 11485916
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
[TBL] [Abstract][Full Text] [Related]
10. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis.
Junbo H; Li Q; Zaide W; Yunde H
In Vivo; 1999; 13(2):177-80. PubMed ID: 10363175
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma.
Zhu X; Humphrey PA
Urology; 2000 Dec; 56(6):1071-4. PubMed ID: 11113771
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum hepatocyte growth factor/scatter factor levels in inflammatory lung disease.
Maeda J; Ueki N; Hada T; Higashino K
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1587-91. PubMed ID: 7582299
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor/scatter factor and prostate cancer: a review.
Hurle RA; Davies G; Parr C; Mason MD; Jenkins SA; Kynaston HG; Jiang WG
Histol Histopathol; 2005 Oct; 20(4):1339-49. PubMed ID: 16136515
[TBL] [Abstract][Full Text] [Related]
14. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.
Davies G; Jiang WG; Mason MD
Clin Cancer Res; 2001 Oct; 7(10):3289-97. PubMed ID: 11595727
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor/scatter factor is implicated in the mode of stromal invasion of uterine squamous cervical cancer.
Shimabukuro K; Ichinose S; Koike R; Kubota T; Yamaguchi M; Miyasaka M; Aso T
Gynecol Oncol; 2001 Nov; 83(2):205-15. PubMed ID: 11606073
[TBL] [Abstract][Full Text] [Related]
16. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro.
McLarty J; Bigelow RL; Smith M; Elmajian D; Ankem M; Cardelli JA
Cancer Prev Res (Phila); 2009 Jul; 2(7):673-82. PubMed ID: 19542190
[TBL] [Abstract][Full Text] [Related]
17. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
19. Levels of hepatocyte growth factor/scatter factor (HGF/SF) in seminal plasma of patients with andrological diseases.
Depuydt CE; De Potter CR; Zalata A; Baekelandt E; Bosmans E; Comhaire FH
J Androl; 1998; 19(2):175-82. PubMed ID: 9570740
[TBL] [Abstract][Full Text] [Related]
20. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
